Recombinomics, Inc. Founder and President, Henry L Niman earned a PhD at the University of Southern California in 1978. He took a postdoctoral position at Scripps Clinic and Research Foundation where he developed monoclonal anti-body technology. In 1982, he developed the flu monoclonal antibody, which is widely used throughout the pharmaceutical, biotech, and research industries. Some of his monoclonal antibodies were distributed worldwide to researchers by the National Cancer Institute. This technology was used to form ProgenX, a cancer diagnostic company that became Ligand Pharmaceuticals.
Dr. Niman subsequently identified protein expression patterns at the University of Pittsburgh. More recently, he became interested in infectious diseases while at Harvard Medical School. He then founded Recombinomics and discovered how viruses rapidly evolve.
Celebrated business futurist, Joel Barker, who is credited with popularizing the term "paradigm shift," shared several worst case scenarios for planet Earth:On the US Education System...Barker commented on the decision by some states to reduce the number of school days in order to save gas. Children in other countries attend school for as much as 60 days longer each year than do... More »
USC Engineering Professor Bart Kosko returned to the show to discuss technology and its future uses. Right now, he said, there is a "gold rush" for patents on nanotechnology devices. Carbon nanotubes are starting to be seen in such products as baseballs and clothes, and they may soon be introduced in flat panel displays, he detailed.